Neuroinflammation in Lewy body dementia

Parkinsonism and Related Disorders

Volumn 21, Issue 12, 2015, Pages 1398-1406

  Surendranathan, Ajenthan ^a   Rowe, James B ^a   O'Brien, John T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Dementia; Lewy body; Microglia; Neuroinflammation; Positron emission tomography

Indexed keywords

ALPHA SYNUCLEIN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; BIOLOGICAL MARKER; CYTOKINE; HLA D ANTIGEN;

CELL ACTIVATION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE DURATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; MICROGLIA; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SYSTEMATIC REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; ADAPTIVE IMMUNITY; ANIMAL; BLOOD; CEREBROSPINAL FLUID; DISEASE MODEL; FORECASTING; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; INFLAMMATION; LEWY BODY DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY;

ADAPTIVE IMMUNITY; ALPHA-SYNUCLEIN; ANIMALS; BIOMARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA-D ANTIGENS; HUMANS; INFLAMMATION; LEWY BODY DISEASE; MICROGLIA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84955694742     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.10.009     Document Type: Review

References (87)

1. Vann Jones S.A., O'Brien J.T. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol. Med. 2014, 44:673-683. 10.1017/S0033291713000494.
2. Hely M.A., Reid W.G.J., Adena M.A., Halliday G.M., Morris J.G.L. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844. 10.1002/mds.21956.
3. Aarsland D., Zaccai J., Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 2005, 20:1255-1263. 10.1002/mds.20527.
4. Lennox G., Lowe J., Landon M., Byrne E.J., Mayer R.J., Godwin-Austen R.B. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J. Neurol. Neurosurg. Psychiatry 1989, 52:1236-1247.
5. Perry R.H., Irving D., Blessed G., Perry E.K., Fairbairn A.F. Clinically and neuropathologically distinct form of dementia in the elderly. Lancet 1989, 1:166.
6. McGeer Patrick L., McGeer E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013, 126:479-497. 10.1007/s00401-013-1177-7.
7. Latta C.H., Brothers H.M., Wilcock D.M. Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience 2014, 10.1016/j.neuroscience.2014.09.061.
8. Lee Y.J., Han S.B., Nam S.Y., Oh K.W., Hong J.T. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 2010, 33:1539-1556. 10.1007/s12272-010-1006-7.
9. Morales I., Guzmán-Martínez L., Cerda-Troncoso C. Farías G a, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell Neurosci. 2014, 8:112. 10.3389/fncel.2014.00112.
10. Ginhoux F., Lim S., Hoeffel G., Low D., Huber T. Origin and differentiation of microglia. Front. Cell Neurosci. 2013, 7:45. 10.3389/fncel.2013.00045.
11. Nayak D., Roth T.L., McGavern D.B. Microglia development and function. Annu. Rev. Immunol. 2014, 32:367-402. 10.1146/annurev-immunol-032713-120240.
12. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318. 10.1126/science.1110647.
13. Gao H., Liu B., Zhang W., Hong J. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 2003, 17:1954-1956. 10.1096/fj.03-0109fje.
14. Prinz M., Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014, 15:300-312. 10.1038/nrn3722.
15. Ajami B., Bennett J.L., Krieger C., McNagny K.M., Rossi F.M.V. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 2011, 14:1142-1149. 10.1038/nn.2887.
16. Perry V.H., Holmes C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 2014, 10:217-224. 10.1038/nrneurol.2014.38.
17. Gao H.-M., Hong J.-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29:357-365. 10.1016/j.it.2008.05.002.
18. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518. 10.1016/j.nbd.2009.11.004.
19. Fan Z., Aman Y., Ahmed I., Chetelat G., Landeau B., Ray Chaudhuri K., et al. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement. 2014, 1-14. 10.1016/j.jalz.2014.06.016.
20. Gerhard A., Banati R.B., Goerres G.B., Cagnin A., Myers R., Gunn R.N., et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003, 61:686-689.
21. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419. 10.1016/j.nbd.2008.08.001.
22. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., et al. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467. 10.1016/S0140-6736(01)05625-2.
23. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175. 10.1002/ana.20338.
24. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412. 10.1016/j.nbd.2005.08.002.
25. Braak H., Tredici K Del, Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211. 10.1016/S0197-4580(02)00065-9.
26. Edison P., Ahmed I., Fan Z., Hinz R., Gelosa G., Ray Chaudhuri K., et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013, 38:938-949. 10.1038/npp.2012.255.
27. Iannaccone S., Cerami C., Alessio M., Garibotto V., Panzacchi A., Olivieri S., et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Park. Relat. Disord. 2013, 19:47-52. 10.1016/j.parkreldis.2012.07.002.
28. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
29. Fauvet B., Mbefo M.K., Fares M.B., Desobry C., Michael S., Ardah M.T., et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 2012, 287:15345-15364. 10.1074/jbc.M111.318949.
30. Lashuel H.A., Overk C.R., Oueslati A., Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 2013, 14:38-48. 10.1038/nrn3406.
31. Wang W., Perovic I., Chittuluru J., Kaganovich A., Nguyen L.T.T., Liao J., et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17797-17802. 10.1073/pnas.1113260108.
32. Bartels T., Choi J.G., Selkoe D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110. 10.1038/nature10324.
33. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542. 10.1096/fj.04-2751com.
34. Zhang W., Dallas S., Zhang D., Guo J.-P., Pang H., Wilson B., et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007, 55:1178-1188. 10.1002/glia.20532.
35. Theodore S., Cao S., Mclean P.J., Standaert D.G. Targeted Overexpression of Human > -Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease. J. Neuropathol. Exp. Neurol. 2008, 67:1149-1158.
36. Daniele S.G., Béraud D., Davenport C., Cheng K., Yin H., Maguire-Zeiss K.A. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal 2015, 8. ra45. 10.1126/scisignal.2005965.
37. Kim W.S., Kågedal K., Halliday G.M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 2014, 6:73. 10.1186/s13195-014-0073-2.
38. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., et al. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 2013, 61:349-360. 10.1002/glia.22437.
39. Kim C., Ho D.H., Suk J.E., You S., Michael S., Kang J., et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4:1562. 10.1038/ncomms2534.
40. Nash K.R., Moran P., Finneran D.J., Hudson C., Robinson J., Morgan D., et al. Fractalkine over expression suppresses α -synuclein-mediated neurodegeneration. Mol. Ther. 2015, 23:17-23. 10.1038/mt.2014.175.
41. 2-dependent Lyn phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2015, 10.1073/pnas.1417883112.
42. Kim C., Cho E.D., Kim H.K., You S., Lee H.J., Hwang D., et al. Β1-Integrin-dependent migration of microglia in response to neuron-released Α-synuclein. Exp. Mol. Med. 2014, 46:e91. 10.1038/emm.2014.6.
43. Sharma N., Nehru B. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation. Neurochem. Int. 2015, 87:92-105. 10.1016/j.neuint.2015.06.004.
44. Tanaka S., Ishii A., Ohtaki H., Shioda S., Yoshida T., Numazawa S. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J. Neuroinflammation 2013, 10:143. 10.1186/1742-2094-10-143.
45. Wang M.X., Cheng X.Y., Jin M., Cao Y.L., Yang Y.P., Wang J.D., et al. TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells. Exp. Neurol. 2015, 271:112-121. 10.1016/j.expneurol.2015.05.008.
46. Boza-Serrano A., Reyes J.F., Rey N.L., Leffler H., Bousset L., Nilsson U., et al. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol. Commun. 2014, 2:156. 10.1186/s40478-014-0156-0.
47. Daher J.P.L., Volpicelli-Daley L.A., Blackburn J.P., Moehle M.S., West A.B. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:9289-9294. 10.1073/pnas.1403215111.
48. Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., Rábano A., Kirik D., et al. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet. 2012, 21:3173-3192. 10.1093/hmg/dds143.
49. Cao S., Standaert D.G., Harms A.S. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J. Neuroinflammation 2012, 9:259. 10.1186/1742-2094-9-259.
50. Harms A.S., Cao S., Rowse A.L., Thome A.D., Li X., Mangieri L.R., et al. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 2013, 33:9592-9600. 10.1523/JNEUROSCI.5610-12.2013.
51. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J. Neuroinflammation 2007, 4:2. 10.1186/1742-2094-4-2.
52. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
53. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526. 10.1007/s00401-003-0766-2.
54. Brochard V., Combadière B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192. 10.1172/JCI36470.
55. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
56. Loeffler D.A., Camp D.M., Conant S.B. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J. Neuroinflammation 2006, 3:29. 10.1186/1742-2094-3-29.
57. Togo T., Iseki E., Marui W., Akiyama H., Uéda K., Kosaka K. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J. Neurol. Sci. 2001, 184:71-75. 10.1016/S0022-510X(00)00498-6.
58. Mackenzie I.R. Activated microglia in dementia with Lewy bodies. Neurology 2000, 55:132-134.
59. Shepherd C.E., Thiel E., McCann H., Harding A.J., Halliday G.M. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch. Neurol. 2000, 57:817-822.
60. Wahner A.D., Sinsheimer J.S., Bronstein J.M., Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol. 2007, 64:836-840.
61. McGeer P.L., Yasojima K., McGeer E.G. Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease. Neurosci. Lett. 2002, 326:67-69. 10.1016/S0304-3940(02)00300-2.
62. Rayaprolu S., Mullen B., Baker M., Lynch T., Finger E., Seeley W.W., et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 2013, 8:19. 10.1186/1750-1326-8-19.
63. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785. 10.1038/ng.642.
64. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649. 10.1016/S0140-6736(10)62345-8.
65. Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 2014, 46:989-993. 10.1038/ng.3043.
66. Wissemann W.T., Hill-Burns E.M., Zabetian C.P., Factor S.A., Patsopoulos N., Hoglund B., et al. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet. 2013, 93:984-993. 10.1016/j.ajhg.2013.10.009.
67. Kannarkat G.T., Cook D.A., Lee J.K., Chang J., Chung J., Sandy E., et al. Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: an observational and case-control study. NPJ Park Dis. 2015, 1:15002. 10.1038/npjparkd.2015.2.
68. Meeus B., Theuns J., Van Broeckhoven C. The genetics of dementia with Lewy bodies: what are we missing?. Arch. Neurol. 2012, 69:1113-1118. 10.1001/archneurol.2011.3678.
69. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 2008, 167:90-95. 10.1093/aje/kwm260.
70. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 1999, 100:34-41.
71. Hu Y., Yu S., Zuo L., Cao C., Wang F., Chen Z.J., et al. Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation. Neurology 2015, 84:888-894. 10.1212/WNL.0000000000001308.
72. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G.P., Rombos A., Zoga M., et al. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol. Scand. 2007, 116:374-379. 10.1111/j.1600-0404.2007.00894.x.
73. Bas J., Calopa M., Mestre M., Mollevi D.G., Ambrosio S., Buendia E. Lymphocyte populations in Parkinson ' s disease and in rat models of parkinsonism. J. Neuroimmunol. 2001, 113:146-152.
74. Song I.U., Kim Y.D., Cho H.J., Chung S.W. Is Neuroinflammation involved in the development of Dementia in patients with Parkinson's disease?. Intern Med. 2013, 52:1787-1792. 10.2169/internalmedicine.52.0474.
75. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O., et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 2013, 9:131-140. 10.1038/nrneurol.2013.10.
76. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
77. Blum-Degen D., Müller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 1995, 202:17-20. 10.1016/0304-3940(95)12192-7.
78. Müller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 1998, 98:142-144.
79. Yu S.-Y., Zuo L.-J., Wang F., Chen Z.J., Hu Y., Wang Y.J., et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 2014, 14:113. 10.1186/1471-2377-14-113.
80. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580. 10.1002/ana.22311.
81. Miyajima M., Nakajima M., Motoi Y., Moriya M., Sugano H., Ogino I., et al. Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLoS One 2013, 8:e74453. 10.1371/journal.pone.0074453.
82. Mollenhauer B., Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov. Disord. 2009, 24:1411-1426. 10.1002/mds.22510.
83. Schade S., Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res. Ther. 2014, 6:72. 10.1186/s13195-014-0072-3.
84. Ernst A., Morgenthaler N.G., Buerger K., Dodel R., Noelker C., Sommer N., et al. Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. J. Neuroimmunol. 2007, 189:169-174. 10.1016/j.jneuroim.2007.07.009.
85. Gagne Joshua J., Power M. Anti-inflammatory drugs and risk of Parkinson disease. Neurology 2010, 74:995-1002.
86. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26:769-779.
87. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674. 10.1093/brain/awh625.